Abstract. Genetic alterations have been defined as the hallmark of cancers as they are responsible for the differences between normal and malignant phenotypes. A widely accepted approach to study genetic instability is to identify cancer-related genes, in particular, the two major groups of growth regulatory genesoncogenes and tumour suppressor genes. Using the technique of suppression subtractive hybridisation, we identified a novel gene transcript, designated as HEPT3. RT-PCR demonstrated that HEPT3 was overexpressed in 87% (20/23) of HCC patients and in 4/5 HCC cell lines tested. Sequence analyses performed on the full-length cDNA revealed that HEPT3 is an intronless gene mapped to human chromosome 6q13-14. The gene transcript lacks an extensive open reading frame and contains an Alu sequence near the 5' terminus, indicating that HEPT3 encodes a noncoding RNA. Antisense studies on the HCC cell line HepG2 showed that, when HEPT3 expression level was reduced, cell proliferation rate was inhibited by ~5-fold and cell colony formation was reduced by at least 50%. Our data suggest that the novel gene HEPT3 may function through its noncoding RNA and its overexpression may play a role in hepatocarcinogenesis.
Introduction
Despite some advances in diagnosis and treatment, the prognosis of hepatocellular carcinoma (HCC) remains extremely poor accounting for almost one million deaths annually (1) . The need of improving the overall outlook of HCC has urged scientists to delineate the yet mysterious mechanisms of hepatocarcinogenesis. Genetic alterations have been defined as the hallmark of cancers because they are responsible for the differences between normal and malignant phenotypes. A widely accepted approach to study genetic instability is to identify cancer-related genes, in particular, the two major groups of growth regulatory genes -oncogenes and tumour suppressor genes. The activation of oncogenes and inactivation of tumour suppressor genes play critical roles in the mechanisms of cancer development. These genes can induce malignant transformation when inappropriately expressed as a result of mutation, deletion, amplification or rearrangement. Studies on the genetic alterations in HCC have recently increased, reporting genes either up-or downregulated or lost in hepatocellular carcinoma (2) (3) (4) (5) (6) (7) (8) . A considerable number of novel genes that are involved in hepatocarcinogenesis have hence emerged.
Exploring genes associated with HCC, we identified a novel gene, HEPT3, which is frequently overexpressed in HCC. HEPT3 is intronless and may function through its noncoding RNA. In this study, we report the identification and characterisation of the novel gene HEPT3 as well as the potential role of HEPT3 in liver tumorigenesis.
Materials and methods
Specimens and cell culture. A total of 23 pairs (tumour and non-tumour) of liver specimens and 2 pairs of colon specimens were collected after surgical resection from the No. 3 Hospital of Chongqing in China. Each sample was snap-frozen and stored in liquid nitrogen before experiment. The final diagnosis of HCC and colon cancer was confirmed by histological examination. The cell lines used in the study were mainly purchased from the American Type Culture Collection and maintained in the recommended media and culture conditions.
Suppression subtractive hybridisation.
The technique of suppression subtractive hybridisation (SSH) was used to compare the mRNA profiles of HCC and its adjacent nontumourous liver tissues of a randomly chosen HCC patient. SSH was performed by using the PCR Select cDNA subtraction kit (Clontech, Palo Alto, CA, USA). The manufacturer's instructions were strictly followed. The SSH products, cDNA fragments representing the gene transcripts upregulated in Identification of a novel gene HEPT3 that is overexpressed in human hepatocellular carcinoma and may function through its noncoding RNA HCC, were cloned into pGEM-T vector (Promega, Madison, WI, USA) and sequenced.
Rapid amplification of cDNA ends. Rapid amplification of cDNA ends (RACE) was employed to isolate the full-length cDNA of HEPT3. RACE was performed with the Human Liver Marathon-Ready cDNA kit (Clontech) using the HEPT3-specific primers (Table I) in combination with the provided adapter primer AP1 or nested adapter primer AP2 to amplify the 5' and 3' portions of the HEPT3 transcript. The RACE products were cloned into pGEM-T vector and sequenced. Primers T3full-forward and T3full-reverse (Table I) at the 5'-and 3'-end of HEPT3 cDNA were then designed to generate the full-length cDNA by end-to-end PCR. The full-length cDNA was cloned into pGEM-T and sequenced.
Reverse transcription-polymerase chain reaction (RT-PCR).
Semi-quantitative RT-PCR was performed with the OneStep RT-PCR kit (Qiagen, Hilden, Germany) while real-time RT-PCR was performed with the LightCycler RNA amplification kit SYBR Green I (Roche, Basel, Switzerland). To determine the mRNA level of HEPT3, primers T3-forward and T3-reverse (Table I) Table I . Sequence information and applications of the primers. 
Cloning of the full-length Reverse TCCTTATTTCAACAGTGTTCTTCTC cDNA into the pGEM-T vector
Cloning of the HEPT3 antisense Reverse Cgaattc a TACTCCCAGTGTAACATAAG sequence into the pcDNA3.1 vector
The letters in lower case are the sequences of the restriction enzyme cutting sites XhoI and EcoRI incorporated into the forward and the reverse primers, respectively.
ended with 10 min at 72˚C. ß-actin served as an internal control. RT-PCR products were analysed by gel electrophoresis. The real-time RT-PCR conditions were: (1) 55˚C for 10 min; (2) 95˚C for 10 sec; and (3) for PCR amplification, 45 cycles of 5 sec at 95˚C, 10 sec at 55˚C, and 12 sec at 72˚C. The relative expression level of HEPT3 in each sample was presented in fold computed against the expression level of the internal control GAPDH.
Northern blot analysis. Total RNA (40 μg) was separated on a 1% formaldehyde/MOPS [3-(N-morpholino) propanesulfonic acid] gel and transferred to Hybond-N + (Amersham, Germany) membrane by capillary blotting. Labeling of HEPT3 cDNA probe (nucleotides 645-1199) and hybridisation were carried out by using the DIG High Prime DNA labeling and detection starter kit I (Roche) according to the manufacturer's procedures.
Antisense plasmid construct and transfection studies. The antisense construct of HEPT3 was generated by PCR with primers AS-forward and AS-reverse (Table I) , and cloned into the pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA). Transfections were carried out with the Lipofectamine Plus Reagents (Invitrogen). To establish stable transfection, HepG2 cells transfected with either the antisense HEPT3 plasmid or pcDNA3.1 vector were selected in the medium containing 800 μg/ml of G418 (Sigma, St. Louis, MO, USA) for 1 month, and then cloned and propagated. Real-time RT-PCR was performed to examine the mRNA levels of HEPT3 in a number of cell clones. Three cell clones, namely HEPT3-AS1, HEPT3-AS2 and HEPT3-AS3, with a significant reduction of HEPT3, were selected for further study. Two cell clones with pcDNA3.1 vector and the parental cells served as controls. To assess the rate of cell proliferation, ~2x10 4 cells were seeded and cultured in 6-well plates. At every 24 h for 5 days, both microscopic analysis and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay were performed to evaluate the cell density and viability, respectively. To establish the base line of cell proliferation, MTT assay was carried out once the cells had attached to the culture dishes on the day of plating. The growth rate of each cell line was presented as a fold increase in cell viability against the respective base line. For colony formation, HepG2 cells transfected with antisense HEPT3 construct or the vector alone were cultured in the medium containing 800 μg/ml of G418 for 3 weeks without trypsinisation. The cell colonies formed at the end of experiment were visible and the number of colonies in each plate was quantitated.
Bioinformatics and statistical analysis. Bioinformatics was carried out through database searches facilitated by the National Center for Biotechnology Information (NCBI), and motif searches with the RepeatMasker program (9). Software InStat 3.0 (GraphPad, San Diego, CA, USA) was use for statistical analysis. For a small sample size (n=6), the MannWhitney test was performed to compare two means while the nonparametric ANOVA for more than two means. Paired t-test was used to assess data with sample size >6. The Fisher's exact test was used to reveal the correlation between HEPT3 overexpression and the clinicopathological parameters in 23 HCC patients. P<0.05 was considered significant.
Results

Identification of the novel gene HEPT3 in hepatocellular carcinoma.
Using the technique of suppression subtractive hybridisation, we compared mRNA expression profiles of HCC and its adjacent non-tumourous liver tissue obtained from a randomly chosen HCC patient (No. 8 in Fig. 2A) , and cloned 134 transcripts that were upregulated in HCC (data not shown). Five novel genes were identified as they did not have significant homology to known genes when subjected to database search. The differential expression of the five genes was confirmed by RT-PCR in the same HCC patient (Fig. 1) . However, when screened against a panel of patients, only HEPT3 appeared to be constantly upregulated in HCC and was therefore chosen for further investigations.
Frequent upregulation of HEPT3 in HCC.
Semi-quantitative RT-PCR was used to examine the expression of HEPT3 in 23 HCC specimens. The results showed that the expression of HEPT3 was elevated in 87% (20/23) of the HCC samples ( Fig. 2A) . Real-time RT-PCR was performed to determine the mRNA levels of HEPT3 in the liver specimens. In addition to the reproducible frequency of HEPT3 overexpression in HCC, real-time RT-PCR revealed an average of 2.5-fold upregulation of HEPT3 in HCCs compared to their adjacent non-tumourous liver tissues (P<0.0001; Fig. 2B ). Moreover, real-time RT-PCR analysis was performed in tissues and cell lines of a variety of human malignancies, including cancers of the liver, colon, skin, brain, breast and blood (Fig. 3) . The results showed an overexpression of HEPT3 in 4 of the 5 
-------------------------------------------------
a The identities and personal data of all the patients are strictly kept confidential. Grade, histological differentiation of HCC. NS, not significant; P was revealed by the Fisher's exact test.
HCC cell lines, but the upregulation of HEPT3 appeared significantly less in tissues and cell lines derived from other tumour types. The data indicate that HEPT3 overexpression is common in HCC, suggesting that the gene may be associated with the tumorigenesis of hepatocytes. However, no significant correlations were observed between HEPT3 overexpression and the clinicopathologic parameters in the 23 HCC patients (Table II) . Sequence analysis of HEPT3 full-length cDNA. Four HEPT3 gene-specific primers designed on the fragment of 700 bp obtained by SSH, as indicated in Fig. 4B , were used in the two consecutive rounds of 5' and 3' RACE reactions. The respective RACE products, ~1.6 kb and ~0.7 kb fragments (Fig. 4A) , were cloned and sequenced. The overlapping sequences of the SSH and the 5' and 3' RACE products were aligned to obtain the full-length cDNA of HEPT3 of ~2.7 kb (GenBank AY374441). As shown in Fig. 4B , the sequence contained a consensus polyadenylation signal, AATAAA, 23 bp upstream of the poly(A) tail at the 3' terminus. Eleven copies of the mRNA destabilisation motif, AUUUA (ATTTA in the cDNA sequence) were identified throughout the sequence. Furthermore, through the RepeatMasker program (9), a 300-bp long Alu repetitive element was identified between the nucleotides 73 and 372 on the HEPT3 cDNA sequence.
HEPT3, an intronless gene mapped to chromosome 6q13-14.
To determine the localisation of HEPT3 on human chromosomes, the HEPT3 full-length cDNA sequence was subjected to searches against the human genome database of the NCBI algorithm. The results showed that HEPT3 was specifically mapped to the human chromosome 6q13-14 (Fig. 5AI) .
Comparative analysis showed that HEPT3 cDNA was collinear to the genomic sequence (GenBank AL591480), indicating that the gene HEPT3 is intronless (Fig. 5AII) . Northern blot analysis was performed using a cDNA probe without the HEPT3 Alu element to avoid non-specific hybridisation. The results revealed three differently sized signals of 3.3, 2.7 and 2.0 kb (Fig. 5AIV) , suggesting that HEPT3 may have isoforms. Indeed, database analysis revealed two uncharacterised full-length cDNAs that matched both the cDNA sequence and the chromosomal location of HEPT3 ( Fig. 5AIII) . One was a 3211-bp human cDNA (GenBank AK130104), which contained the entire HEPT3 cDNA in its 3' region. The other was a 1743-bp full-length cDNA of human fetal brain (GenBank CR599670), which was 99% homologous to the 3' portion of HEPT3 cDNA. On the Northern blot, the ~2.7 kb band with the strongest signal appeared to correspond to the full-length HEPT3 cDNA while the ~3.3 and ~2 kb bands corresponded to the two isoforms identified in the database. Similar to HEPT3, both transcripts were encoded by intronless genomic DNA. These findings indicate that HEPT3 and its variants may be transcribed from the same genomic DNA.
HEPT3, a potential noncoding RNA. The NCBI ORFinder revealed a high density of stop codons in all the 6 theoretical reading frames (Fig. 5B) . Although numerous start codons were scattered throughout the HEPT3 gene, the frequent stop codons resulted in a lack of an extensive open reading frame. Similar observations were obtained when the other two HEPT3 isoforms, the 3.2-kb and 1.7-kb transcripts, were analysed. These data suggest that HEPT3 may not possess coding capacity. However, searches with both the full-length and fragmented HEPT3 sequences failed to reveal any significant homology to the known microRNAs in the available databases.
Reduction of HepG2 cell growth rate by antisense HEPT3.
As HEPT3 was markedly upregulated in HCC cell lines, we employed the antisense approach to interfere with the expression of HEPT3 in HepG2 cells and then to evaluate the involvement of HEPT3 in regulating cell growth. The antisense plasmid was constructed with a partial cDNA of HEPT3 in the antisense orientation (Fig. 6A) . The Alu element was excluded to avoid binding to non-specific sequences. The endogenous HEPT3 mRNA levels were clearly decreased by antisense HEPT3 in three clones (Fig. 6D ). Light microscopy ( Fig. 6B ) and MTT assay (Fig. 6C ) revealed that the cell proliferation rate of these three cell clones was reduced ~5-fold on days 4 and 5 (P<0.001) when compared to the controls, two cell clones transfected with the empty vector and the parental HepG2 cells. In addition, disruption of HEPT3 reduced the colony formation of HepG2 cells. Not only did the antisense HEPT3 decrease the number of colonies by >50% (P<0.001) but also the size and cell density of the colonies (Fig. 6E) . These data implicate that overexpressed HEPT3 exerts proliferative effect on the HCC cells.
Discussion
Using suppression subtractive hybridisation to compare the mRNA expression patterns of HCC and its adjacent nontumourous liver tissue, we identified a novel transcript, HEPT3, which is highly upregulated in 87% of 23 HCC tissues examined. However, no significant correlations could be observed between HEPT3 overexpression and the clinicopathological parameters in the 23 HCC patients. This observation could be due to the high frequency (20/23) of HEPT3 overexpression in the patients and/or the relatively small sample size examined in this study. An elevated expression of HEPT3 was also detected in most (4/5) of the HCC cell lines tested, but no apparent overexpression of HEPT3 was observed in tissues and cell lines of other tumour types. The data indicate that HEPT3 overexpression is specific to HCC, suggesting that the gene may be associated with the tumorigenesis of hepatocytes. Liver-specific genes that are differentially expressed in HCC have been identified. For example, the human LFIRE-1/HFREP-1 is frequently downregulated or lost in HCC (10) . Hopefully, the emerging of HEPT3 will shed new light on liver carcinogenesis.
The mechanism responsible for regulating HEPT3 expression is still elusive. The polyadenylated transcript of HEPT3 contains eleven copies of the mRNA destabilisation motif, AUUUA. Such motifs have been reported in lymphokines, cytokines and proto-oncogene mRNAs; and have been proposed to interact with the AU-binding factor that degrades mRNA (11) . This finding offers a clue that the RNA levels of HEPT3 may be regulated by mechanisms involving RNA stability.
The gene HEPT3 encodes a transcript of ~2.7 kb and displays several intriguing characteristics. The full-length cDNA of HEPT3 is collinear to its genomic DNA, indicating that HEPT3 represents an intronless gene. Naturally intronless genes account for <6% of the genes in human (12) . Since intronless genes do not require post-transcriptional splicing, they can be transcribed more efficiently leading to a potentially faster rate of expression, greater abundance and higher fidelity. Classic examples of intronless proto-oncogenes are the myc (13) and c-jun (14) genes. The lack of intron/exon boundaries in the genomic sequence implies that alternative splicing of HEPT3 is unlikely to occur. However, Northern blot analysis detected three differently sized transcripts, suggesting that HEPT3 has isoforms. Database analyses revealed two uncharacterised full-length cDNAs matching with HEPT3 both in sequence and in chromosomal location. These findings indicate that HEPT3 and its variants are transcribed from the same genomic DNA. However, the mechanism of generating these transcripts by the DNA machinery remains unclear.
Another striking feature of HEPT3 is the high density of stop codons in all the reading frames, resulting in a lack of extensive open reading frame. In addition, an Alu repetitive element was identified in the HEPT3 transcript. The presence of short interspersed repetitive sequences (SINEs) and other repeats is a frequent event in non-translatable transcripts (15) , but rare in translated transcripts (16) . Collectively, the atypical structural features of the cDNA suggest that HEPT3 may function as a noncoding RNA. Two examples of relatively well-studied mammalian genes that act at the RNA level are XIST (X (inactive)-specific transcript) and H19 (17, 18) . XIST RNA coats one of the two X chromosomes in females, resulting in transcriptional silencing of the X chromosome. H19 has been implicated in imprinting of the insulin-like growth factor 2 gene important for tumour suppression (19) . Moreover, many miRNAs (microRNAs), another group of noncoding RNAs, have been implicated in carcinogenesis including HCC (20) (21) (22) . However, database searches failed to reveal significant homology or complementarities between HEPT3 sequences and the known miRNAs.
The gene HEPT3 is mapped to human chromosome 6q13-14. Chromosome 6 is best recognised for the major histocompatibility complex (MHC) that is critical to the human immune response. Additionally, it was documented to carry genes related to genetic diseases such as arthritis (23) , diabetes (24) , schizophrenia (25) and cancers. Gains in chromosome 6 have also been reported in HCC (26) ; however, it is unclear if HEPT3 is involved in such gains.
To determine if HEPT3 mRNA contributes to hepatocyte survival, we used an antisense inhibition approach to interfere with the biological activity of HEPT3. Suppression of the endogenous HEPT3 mRNA by antisense HEPT3 significantly inhibited both cell proliferation and colony formation of HepG2 cells, demonstrating that antisense HEPT3 exhibits antiproliferative effect on the HCC cells that express the endogenous HEPT3 gene. These results implicate that transcriptional activation of the HEPT3 gene may stimulate the oncogenic pathway that induces cell proliferation.
In conclusion, the gene HEPT3 is more commonly upregulated in HCC than in other tumour types. HEPT3 is an intronless gene and maps to chromosome 6q13-14. Its transcript displays the typical characteristics of noncoding RNA, including the lack of extensive ORF and the presence of an Alu sequence. Antisense studies revealed that the growth of HCC cells was significantly suppressed when HEPT3 expression level was reduced. The data indicate that HEPT3 may function through its noncoding RNA and play a role in the malignant transformation of hepatocytes. Further studies will be carried out to elucidate how HEPT3 transcription is activated in hepatocarcinogenesis and then promotes the progression of HCC.
